Arecor Therapeutics PLC Cash Flow-to-Debt Ratio
Arecor Therapeutics PLC cash flow-to-debt ratio. Arecor Therapeutics PLC (AREC) has a Cash Flow-to-Debt Ratio of -0.70x as of December 2025, meaning its operating cash flow of GBX-1.15 Million could theoretically repay -1% of its total liabilities (GBX1.65 Million) in one year. Check AREC cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Arecor Therapeutics PLC (2018–2025)
Cash flow-to-debt ratio of Arecor Therapeutics PLC from 2018 to 2025. Historical debt coverage capacity for Arecor Therapeutics PLC across 9 annual periods. Also explore Arecor Therapeutics PLC net asset momentum to track the company's year-over-year net asset growth rate.
Arecor Therapeutics PLC Cash Flow-to-Debt Ratio by Year (2018–2025)
Arecor Therapeutics PLC cash flow-to-debt ratio by year from 2018 to 2025. Year-by-year debt coverage analysis for Arecor Therapeutics PLC. For the full cash flow conversion analysis, see AREC operating cash flow.
| Year | CF-to-Debt Ratio | Operating CF (GBX) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.39x | GBX-2.29 Million | GBX1.65 Million | ▲ +48.8% |
| 2024 | -2.71x | GBX-9.15 Million | GBX3.37 Million | ▼ -171.8% |
| 2023 | -1.00x | GBX-5.84 Million | GBX5.85 Million | ▲ +60.1% |
| 2022 | -2.50x | GBX-10.78 Million | GBX4.31 Million | ▼ -8.9% |
| 2021 | -2.30x | GBX-5.45 Million | GBX2.37 Million | ▼ -334.4% |
| 2020 | -0.53x | GBX-1.86 Million | GBX3.51 Million | ▼ -26.6% |
| 2019 | -0.42x | GBX-458.80K | GBX1.10 Million | ▲ +79.4% |
| 2019 | -2.03x | GBX-2.50 Million | GBX1.23 Million | ▼ -475.0% |
| 2018 | -0.35x | GBX-492.57K | GBX1.40 Million | — |